Additional supporting information may be found in the online version of this article at the publisher's web-site.


Table S1. Summary of ΔΔQTcI (90% CI) for QTcI on Day 5 for Both Doses of Pasireotide and Moxifloxacin at Each Time Point

Table S2. Summary of ΔΔQTcI (90% CI) for QTcI, QTcF, PR and HR by Gender for Both Doses of Pasireotide up to 8 Hours Post-Dose

Table S3. Summary of Pharmacokinetic Parameters for Day 5

Table S4. Most Frequent AEs (≥5% of Subjects in Any Treatment Group), Regardless of Study Drug Relationship

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.